| 2022.04.13 | Research group led by researchers at Dept. of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, published in"Oncogene" on the effect of TM-411 to ameliorate the susceptibility of chemotherapy to pancreatic cancer. |
|---|---|
| 2022.02.03 | FDA designated TM-411 for MDS as an Orphan Drug. |
| 2021.09.10 | First patient enrolled in Phase II clinical trial of TM-411 in triplet combination with venetoclax and azacitidine for AML in US. |
